Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Manning-Geist BL, Gordhandas SB, Giri DD, Iasonos A, Zhou Q, Girshman J, O'Cearbhaill RE, Zamarin D, Lichtman SM, Sabbatini PJ, Tew WP, Li K, McDonnell AS, Aviki EM, Chi DS, Aghajanian CA, Grisham RN.
Manning-Geist BL, et al.
Gynecol Oncol. 2022 Jan;164(1):12-17. doi: 10.1016/j.ygyno.2021.10.087. Epub 2021 Nov 8.
Gynecol Oncol. 2022.
PMID: 34763937
Free PMC article.
Clinical Trial.